Author: Ned Douthat

“Comcast reporting a quarter that looked on the face of it pretty good. But as you might expect, a lot of investors still waiting. There is what they call “a strategic overhang” when it comes to Comcast and its...

“So why do we like Celgene so much, and how come we have time? The main reason I like it is its huge blood cancer drug Revlimid. $1.3 billion sales in 2008. It’s approved by the FDA to treat multiple myeloma....

“…And GM really making real progress with the SUV’s. I mean, I have got to tell you, they have really come alive in that segment, they now lead Ford in that segment.  Other winners just looking at...

This morning Warren Buffett announced his company, Berkshire Hathaway (BRKB), would make its largest acquisition to date in Burlington Northern Sante Fe (BNI).  When Warren makes a move, everyone takes notice.  His...

“I thought the downgrade should have been made 20 points ago. You’ve got a 14 times earnings stock in the 50s. I’m not going to back away from it at this level. I’d rather buy it than sell it. It’s...

For all the debate about possible reform to the U.S. medical system, it is easy to forget that the majority of major innovations in drugs and medical devices come from America.  It is worth remembering that even with all...

This has been a week that many investors in Tessera Technologies (TSRA) would just as soon forget.  The stock has fallen more than 25% since the beginning of the week, with the bulk of those losses coming on Friday...

“Third leg is very controversial but we don’t shy from controversy on this show. It’s WellPoint, now what is WellPoint, WellPoint is the HMO that reported an absolute monster yesterday quarter. Earning $1.53...

On Wednesday night’s Mad Money, Jim Cramer paid a compliment to the much maligned CEO of Textron (TXT) by pulling his picture off of the Wall of Shame.  Cramer has been outspoken in his criticisms of Lewis Campbell...